Apremilast
Apremilast is a pharmaceutical drug with 100 clinical trials. Currently 16 active trials ongoing. Historical success rate of 95.8%.
Success Metrics
Based on 68 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
33
Mid Stage
44
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
89.5%
68 of 76 finished
10.5%
8 ended early
16
trials recruiting
100
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Human Laboratory Study of Apremilast for Alcohol Use Disorder
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Clinical Trials (100)
Human Laboratory Study of Apremilast for Alcohol Use Disorder
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Methotrexate Versus Apremilast for Pruritus in Psoriasis
Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis
Apremilast and Adalimumab in Psoriatic Arthritis Patients
Apremilast for Alcohol Use Disorder Treatment in Women and Men
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 100